Lipid modification cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease : final version
This guideline updates for primary prevention, the NICE technology appraisal, Statins for the prevention of cardiovascular events' (TA94, 2007) and reviews and updates the recommendations made in the NICE guideline Lipid Modification (CG67, 2008) for primary and secondary prevention of cardiova...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
London
National Clinical Guideline Centre
2014, July 2014
|
| Series: | NICE clinical guideline
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | This guideline updates for primary prevention, the NICE technology appraisal, Statins for the prevention of cardiovascular events' (TA94, 2007) and reviews and updates the recommendations made in the NICE guideline Lipid Modification (CG67, 2008) for primary and secondary prevention of cardiovascular disease (CVD). The scope for this guideline was limited to the identification and assessment of CVD risk and to the assessment and modification of lipids in people at risk of CVD, or people with known CVD. The guideline development group wishes to make clear that lipid modification should take place as part of a programme of risk reduction which also include attention to the management of all other known CVD risk factors |
|---|---|
| Item Description: | Title from PDF cover. - "This guidance is a partial update of NICE clinical guideline 67 (published 2008) and will replace it" --P. 10 |
| Physical Description: | 1 PDF file (302 pages) illustrations |